dallas glp-1 class action GLP-1-directed NMDA receptor antagonism for obesity treatment GLP-1 receptor agonists are increasingly
Description
has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly and Novo Nordisk
In addition to the ASO, the efficacy of an RNAi directed at PNPLA3, known as LY3849891, is also being evaluated in clinical trials for patients with MASH with PNPLA3 variants (NCT05395481) 64
Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers a medically backed way to reduce hunger, manage blood sugar, and support long-term weight management
Regular screening using validated tools such as the AUDIT-C for alcohol can help track changes
